东方招益债券A
Search documents
机构风向标 | 实丰文化(002862)2025年三季度已披露持仓机构仅1家
Xin Lang Cai Jing· 2025-10-28 01:19
Core Insights - Shifeng Culture (002862.SZ) released its Q3 2025 report on October 28, 2025, indicating a total institutional holding of 4.9001 million shares, representing 2.92% of the total share capital [1] - The institutional holding percentage decreased by 0.79 percentage points compared to the previous quarter [1] - Six public funds were disclosed this period, including Huashang Advantage Industry Mixed A and others, with no new foreign institutional disclosures [1] Institutional Holdings - As of October 27, 2025, there is one institutional investor holding shares in Shifeng Culture, which is Shenzhen High-tech Investment Group Co., Ltd [1] - The total institutional holding has decreased from the previous quarter [1] Public Funds - The report mentions six public funds that were not disclosed in the previous quarter, including Huashang Advantage Industry Mixed A and others [1] Foreign Investment - There were no new foreign institutional disclosures this quarter, with BARCLAYS BANK PLC being the only foreign institution mentioned [1]
吴萍萍2025年三季度表现,东方招益债券A基金季度涨幅0.55%
Sou Hu Cai Jing· 2025-10-27 23:31
Core Insights - Fund manager Wu Pingping oversees two funds, with the best performance in Q3 2025 being the Dongfang Zhaoyi Bond A (022637), which achieved a net value increase of 0.55% [1] Fund Performance Summary - Dongfang Zhaoyi Bond A (022637) has an annualized return of 0.31% and a Q3 increase of 0.55%, with its top holding being Luoyang Jiyi (603993.SH) at 0.41% of net value [2] - Dongfang Zhaoyi Bond C (022638) has an annualized return of 0.30% and a Q3 increase of 0.48%, also holding Luoyang Jiyi (603993.SH) at 0.41% of net value [2] - During Wu Pingping's tenure as manager of Dongfang Growth Return Balanced Mixed Fund (400020), the cumulative return was 2.75% with an average annualized return of 0.74% [2] Stock Adjustment Cases - Notable stock adjustments include: - Shengxunda (300518) was bought in Q2 2016 and sold in Q3 2016, yielding an estimated return of 242.74% with a company performance increase of 8.18% [4] - Huayuan Biological (300401) was held from Q3 2016 to Q4 2017, resulting in a 66.41% estimated return and a company performance increase of 197.91% [5] - ST Gaosheng (000971) was held from Q3 2016 to Q1 2018, resulting in a -48.79% estimated return despite a company performance increase of 35.26% [6]